Publication: Comparison of clinical outcomes between HIV-infected patients with and without HCV co-infection in a resource-limited setting
Issued Date
2012-11-05
Resource Type
ISSN
01251562
Other identifier(s)
2-s2.0-84868121064
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Southeast Asian Journal of Tropical Medicine and Public Health. Vol.43, No.3 (2012), 646-650
Suggested Citation
Nan Nitra Than, Somnuek Sungkanuparph, Wirach Maek-A-Nantawat, Jaranit Kaewkungwal, Punnee Pitisuttithum Comparison of clinical outcomes between HIV-infected patients with and without HCV co-infection in a resource-limited setting. Southeast Asian Journal of Tropical Medicine and Public Health. Vol.43, No.3 (2012), 646-650. Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/14530
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Comparison of clinical outcomes between HIV-infected patients with and without HCV co-infection in a resource-limited setting
Other Contributor(s)
Abstract
Hepatitis C virus (HCV) co-infection is common among HIV-infected patients; its treatment is not affordable in resource-limited settings. This study aimed to compare the morbidity, mortality, immunological and virological outcomes of antiretroviral therapy (ART) between HIV-infected patients with and without HCV co-infection in a setting where HCV infection is rarely treated. A retrospective cohort study was conducted among HIV-infected patients attending Ramathibodi Hospital between 1998 and 2008. We studied 171 HIV-infected patients 57 with and 114 without HCV co-infection. The mean age of patients was 34.6 years and 67.3% were males. There were no differences in demographics, HIV staging, CD4 counts, ART use and ART regimens between the two groups (p > 0.05). All patients who had a CD4 count < 200 cells/mm 3 or had an AIDS-defining illness during following-up were given ART; these consisted of 84.2% and 88.6% of patients with and without HCV co-infection, respectively. Only 4 out of 57 (7%) HCV co-infected patients were treated for HCV infection. During a median (range) follow-up time of 2.9 (1.2-9.8) years, no patients died in either group. The rates of AIDS-defining illnesses and hospitalization in the two groups were similar (p > 0.05). In a resource-limited setting where HCV treatment is not affordable, HCV co-infection does not appear to affect morbidity, mortality or treatment responses to ART. ART may have a greater impact than HCV co-infection on the survival of HCV/HIV co-infected patients. Further studies are needed to assess the long-term impact of HCV co-infection on clinical outcomes in HIV-infected patients without HCV treatment.